AttardLab
@AttardLab
Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.
@AttardLab’s latest finding (nature.com/articles/s4146…) shows that autosome-defined relationship of metastases in lethal prostate cancer is also characterised by their AR gene architectures.
Find out @AttardLab’s latest publication (nature.com/articles/s4146…) showing that lethal prostate cancer progresses to lethal disease via a limited number (two or three) of dominant clones, each harbouring patient-specific androgen receptor gene architectures.
@AttardLab is proud to present its latest publication “Copy number architectures define treatment-mediated selection of lethal prostate cancer clones”🎉 in @NatureComms. Kudos to our team for their hard work! 👍 nature.com/articles/s4146…
Exciting opportunity for computational biologist interested in studying drug resistance in prostate cancer ucl.ac.uk/work-at-ucl/se…
Today is my last day @AttardLab @uclcancer! I’ve had a brilliant time. Been lucky enough to work with lovely people on interesting projects and have learnt a LOT. I’m excited to join @NATCAN_news as senior project manager on newly funded cancer audits rcseng.ac.uk/standards-and-…
We’ve updated our website 🚨. More team members, more publications, more news! Check out attardlab.com for our refreshed look.
Great all day meeting of the STAMPEDE Translational Research Group. So much great work: imaging, pathology, DNA & RNA profiling, big data mining of NHS data. Big papers pending 😊 @ICR_London @MRCCTU @CRUKresearch @ProstateUK @AttardLab
Great opportunity for a trainee oncologist to join our team and become an expert on prostate cancer: atsv7.wcn.co.uk/search_engine/…
Key take homes from STAMPEDE @myESMO #ESMO2022 ⭐️More is not always better for AR axis targeting ⭐️GC is interestingly prognostic even in HR PCa ⭐️Predictive biomarkers remain elusive - curious to see Lum A vs Lum B vs basal for AAP effects Well done again to the Team!🦣🦣
Interesting genomic data from STAMPEDE particularly M0 patients. Can we avoid abiraterone safely in low genomic but high clinical risk M0 HSPC patients? #ESMO2022 interactions not significant but absolute benefits lower.
It's a #STAMPEDE double bill kicking off the prostate proffered paper session at #ESMO22 with Gert presenting LBA62 and @marina_parry with 1358O. Hope to see you there, Sunday 11th, 8.30am Antibes auditorium.
Thrilled to share our 1st translational study looking at accumulation of copy number alterations & clinical progression in #STAMPEDE (rdcu.be/cUWCv). Thanks to funders @ProstateUK @CRUKresearch @PCF_Science @PCR_News & @EmilyGrist1 for driving this. Tweetorial to come!
Another important STAMPEDE paper. Tweetorial and link to paper 👇
5-year follow-up results from #STAMPEDEtrial reveal that adding docetaxel chemotherapy to the standard treatment helps patients with non-metastatic #ProstateCancer to live longer without their disease getting worse. Here’s a 🧵 of the results
1 week to go until our Experts Knowledge Share: 'Targeting Advanced #ProstateCancer with PARP inhibitors: Who, When and Why?' Join the discussion with Drs. Fred Saad, Tanya Dorff @TDorffOnc and Gerhardt Attard @AttardLab Book your place here:👉bit.ly/3HGrjIJ
Join the discussion at our virtual Experts Knowledge Share on; -Efficacy & safety profiles of PARP inhibitors -Testing strategies to predict PARP inhibitor suitability -Data of combination studies with PARP inhibitors register: ow.ly/g8gv50HQFOQ #MedEd @TDorffOnc @AttardLab
15 min podcast in conversation with @thelancet on the latest STAMPEDE results plus a commentary on the trial structure, adding arms to trials and broader implications for clinical trials in general thelancet.com/in-conversatio… @ICR_London @MRCCTU @CR_UK @cancerBRC
The #STAMPEDE trial is looking for a Clinical Trial Manager - a hugely important post. We look forward to working with the successful candidate as part of our translational projects. Apply before 21st Jan, link in tweet below👇
New Year, new job? We're looking for three Clinical Trial Managers to work on exciting, innovative clinical trials. Come and join our team! Apply by 21st Jan. Find out more with the link below atsv7.wcn.co.uk/search_engine/…
Well said Nick. A very good time to thank you for all the hard work you do behind the scenes to ensure that the study has been so successful. 🏴 💪 Hope you are able to have a very well deserved break 🇧🇷 @mattsydes @Silke_Gillessen @PCaParker @MaxParmarMRCUCL Thank you 🙏
I would very much echo this. A huge effort by all concerned with massively important results. The outcomes emphasise why we have been campaigning to maintain trial recruitment during the Pandemic @ICR_London @royalmarsdenNHS @cancerBRC
Adding abiraterone to standard hormone therapy did increase severe side-effects. Adding enzalutamide on top of abiraterone and standard therapy did not provide any additional benefit, but did increase side-effects even more.
Abi/P improves outcomes in men with high risk M0 prostate cancer, important findings but still some open questions to discuss @APCCC_Lugano Congrats @AttardLab et al! authors.elsevier.com/c/1eIQ0V-4XDTv…